#United States #Madison #Accuray #CyberKnife #ARAY

Accuray Reports Fiscal 2027 First Quarter Financial Results

Accuray Incorporated, a leader in radiation therapy solutions, recently disclosed its financial outcomes for the first quarter ended September 30, 2026. Notably, the company aims to expand the potential of radiation therapies and improve patient outcomes through innovative technologies.

Key Highlights

1. Service Revenue Growth: Accuray's service revenue reached $59.2 million, marking a 4% increase year-over-year. When considering constant currency, the growth rate was an impressive 5%, attributed to effective pricing strategies and a nearly 3% rise in the global installed base.
2. Improved Margins: The service gross margin increased to 35.1%, which is a 120-basis point uptick from the previous year. This improvement was predominantly due to strategic pricing initiatives and a reduced service labor cost structure.
3. Controlled Operating Expenses: Total operating expenses for the quarter were reported at $62.6 million, overshadowed by a non-cash goodwill impairment charge of $35.4 million. However, excluding this charge, operating expenses showed a significant decline of 29% compared to the same quarter last year.

These advancements stem from ongoing transformation initiatives that have yielded roughly $13 million in cost and margin improvements, particularly through headcount optimization and efficient utilization of strategic partners.

Strategic Developments

Accuray has reinforced its growth trajectory through strategic agreements, including a partnership with RaySearch aimed at enhancing its online adaptive radiation therapy strategy. Another collaboration with Samsung NeuroLogica is focused on advancing volumetric imaging capabilities for the CyberKnife system, enhancing precision treatment delivery.

Moreover, the long-term data released from the PACE-A study points to a robust eight-year biochemical control rate for Stereotactic Body Radiation Therapy (SBRT), indicating a quality-of-life advantage over traditional surgical methods for many patients.

Financial Overview

The company's total net revenue for Q1 of fiscal 2027 was $86.5 million, reflecting an 8% decrease from the prior year. Specifically, product revenue decreased to $27.3 million, a decrease of 26%, while service revenue experienced an increase. The total gross profit stood at $26.1 million, corresponding to a gross margin of 30.1%, an improvement attributed to higher service margins.

Accuray recognized a substantial gain of approximately $59.6 million on extinguishment of debt from recent financing activities. However, net income could only reach $10.1 million, largely influenced by non-cash items. When adjusted for these, the company reported a net loss of $14 million.

The outlook for fiscal 2027 remains cautious as Accuray transitions from a focus on transformation to execution, aiming to translate customer engagement and innovation opportunities into increased orders and revenue.

Future Guidance

While no formal revenue guidance was issued, Accuray emphasized the importance of leveraging improvements in service margins and cost structures to bolster commercial performance. The management believes the company is primed to execute its strategic priorities effectively, aimed at increasing efficiency and fostering a sustainable growth model.

As they strive for excellence, the upcoming conference call will further elucidate Accuray's strategies and responses to investor queries regarding their operations and market outlook.

In summary, despite the hurdles faced in the past quarter, Accuray has managed to achieve growth in key areas and is poised for a transformative year ahead, focusing on increasing shareholder value and expanding its market presence.